I-MAB Completes Acquisition of Bridge Health Biotech

I-MAB announced the closing of its acquisition of Bridge Health Biotech Co., Ltd. through its wholly owned subsidiary, I-Mab Biopharma Hong Kong Limited. The transaction, governed by an Equity Purchase Agreement dated July 17, 2025, involves an upfront payment of $1.8 million and non-contingent payments of $1.2 million through 2027. Additionally, Bridge Health shareholders may receive up to $3.875 million in milestone payments based on the achievement of certain development and regulatory milestones. This acquisition grants I-MAB rights to bispecific and multi-specific applications, including antibodies and antibody drug conjugates, based on the Claudin 18.2 parental antibody used in I-MAB's givastomig.